TECENTRIQ Drug Use Surveillance(advanced or recurrent non-small cell lung cancer)
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs Atezolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Chugai Pharmaceutical
- 04 Apr 2019 Status changed from recruiting to active, no longer recruiting.
- 20 Apr 2018 Status changed from not yet recruiting to recruiting.
- 19 Apr 2018 New trial record